Low dose application of the TLR7 agonist IMQ treatment exerted a mild but significant effect to promote features of autoimmunity in FVB/N mice in the current study, including splenomegaly and significantly increased plasma ANA antibody levels, although these remained variable and below the positive index in many of the mice. This evidence concerns the gene BTG3 and Splenomegaly.